Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

Abstract Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials suggested greater efficacy of paxlovid, but recent studies indicated comparable potency in older adults. He...

Full description

Bibliographic Details
Main Authors: Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, Amirhossein Karimi, Nicole A. P. Lieberman, Zachary M. Sticher, Pavitra Roychoudhury, Meghan K. Andrews, Rebecca E. Krueger, Michael G. Natchus, George R. Painter, Alexander A. Kolykhalov, Alexander L. Greninger, Richard K. Plemper
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40556-8